Sheila Umlauf
Office Assistant, Yale HealthCards
About
Research
Publications
2026
Pharmaco-behavioral profiling identifies suppressors of autism gene–associated phenotypes in zebrafish
Jamadagni P, Dai Y, Liu Y, Mendes H, Pruitt A, Khan S, Yang L, Huang T, Huang X, Deans P, Balafkan N, Zhao D, Xu G, Liu Y, Li N, Wu W, Fitzpatrick S, Neelakantan U, Chen T, Szialta C, Jin D, Lacadie C, Umlauf S, Papademetris X, Surovtseva Y, Brennand K, Wang Z, Hoffman E. Pharmaco-behavioral profiling identifies suppressors of autism gene–associated phenotypes in zebrafish. Proceedings Of The National Academy Of Sciences Of The United States Of America 2026, 123: e2518846123. PMID: 41838920, PMCID: PMC13012064, DOI: 10.1073/pnas.2518846123.Peer-Reviewed Original ResearchConceptsASD genesAutism spectrum disorder genesAutism spectrum disorderBehavioral phenotypesHigh-throughput assayRegional brain activity deficitsGene mutantsUS Food and Drug AdministrationBrain activity deficitsMutantsMetabolic pathwaysFood and Drug AdministrationEstrogen receptor agonistMitochondrial modulatorsGenesReceptor agonistsPhenotypeSignaling deficitsGlutamatergic neuronsSuppressorMicrotubule inhibitorsCarnitine supplementationSpectrum disorderBehavioral profileDrug rescue
2024
Phosphoenolpyruvate carboxykinase-2 (PCK2) is a therapeutic target in triple-negative breast cancer
Gunasekharan V, Lin H, Marczyk M, Rios-Hoyo A, Campos G, Shan N, Ahmed M, Umlauf S, Gareiss P, Raaisa R, Williams R, Cardone R, Siebel S, Kibbey R, Surovtseva Y, Pusztai L. Phosphoenolpyruvate carboxykinase-2 (PCK2) is a therapeutic target in triple-negative breast cancer. Breast Cancer Research And Treatment 2024, 208: 657-671. PMID: 39177932, DOI: 10.1007/s10549-024-07462-z.Peer-Reviewed Original ResearchMetabolic fluxTriple-negative breast cancerReduced metabolic fluxMDA-MB-231 cellsCell growth in vitroEnzyme assays in vitroMDA-MB-231Potential small molecule inhibitorsPyruvate carboxylaseGrowth in vitroSmall molecule inhibitorsIn silico screeningEnzyme assaysAssay in vitroEnzymatic assayCell lines in vitroEnzyme activityGrowth inhibitory activityBT-549Breast cancerIn vitro screeningBreast cell lines in vitroPhosphoenolpyruvateSignificant growth inhibitory activityLines in vitro
2022
831 Proteasome inhibitor functional profiling in CTCL
Xu S, Lewis J, King A, Umlauf S, Carlson K, Foss F, Girardi M. 831 Proteasome inhibitor functional profiling in CTCL. Journal Of Investigative Dermatology 2022, 142: s144. DOI: 10.1016/j.jid.2022.05.845.Peer-Reviewed Original ResearchComprehensive Analysis of Metabolic Isozyme Targets in Cancer
Marczyk M, Gunasekharan V, Casadevall D, Qing T, Foldi J, Sehgal R, Shan NL, Blenman KRM, O'Meara TA, Umlauf S, Surovtseva YV, Muthusamy V, Rinehart J, Perry RJ, Kibbey R, Hatzis C, Pusztai L. Comprehensive Analysis of Metabolic Isozyme Targets in Cancer. Cancer Research 2022, 82: 1698-1711. PMID: 35247885, PMCID: PMC10883296, DOI: 10.1158/0008-5472.can-21-3983.Peer-Reviewed Original ResearchConceptsPotential therapeutic targetAcetyl-CoA carboxylase 1Therapeutic targetCancer typesCell linesBreast cancer viabilityPatient-derived xenograftsNovel metabolic targetsCorresponding cell linesExpression patternsDrug treatmentMatching normal tissuesRelated commentaryTumor growthMalignant transformationSmall molecule inhibitionCancer viabilityCancer Cell Line EncyclopediaNormal tissuesMetabolic vulnerabilitiesCarboxylase 1Anticancer therapyCellular changesCell proliferationMetabolic reprogramming
2020
854 Functional drug screening identifies candidate synergistic combinations for CTCL therapy
Yumeen S, Mirza F, Lewis J, King A, Kim S, Carlson K, Umlauf S, Surovtseva Y, Foss F, Girardi M. 854 Functional drug screening identifies candidate synergistic combinations for CTCL therapy. Journal Of Investigative Dermatology 2020, 140: s111. DOI: 10.1016/j.jid.2020.03.870.Peer-Reviewed Original ResearchScreening Novel Agent Combinations to Expedite CTCL Therapeutic Development
Mirza FN, Yumeen S, Lewis JM, King ALO, Kim S, Carlson KR, Umlauf S, Surovtseva YV, Foss FM, Girardi M. Screening Novel Agent Combinations to Expedite CTCL Therapeutic Development. Journal Of Investigative Dermatology 2020, 141: 217-221. PMID: 32534802, DOI: 10.1016/j.jid.2020.05.097.Peer-Reviewed Original ResearchJAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL
Yumeen S, Mirza FN, Lewis JM, King ALO, Kim SR, Carlson KR, Umlauf SR, Surovtseva YV, Foss FM, Girardi M. JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL. Blood Advances 2020, 4: 2213-2226. PMID: 32437546, PMCID: PMC7252559, DOI: 10.1182/bloodadvances.2020001756.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaJAK inhibitionCTCL cellsMalignant cutaneous T-cell lymphomasAdvanced cutaneous T-cell lymphomaTreatment of CTCLAvailable systemic treatment optionsSkin-homing T lymphocytesSystemic treatment optionsT-cell lymphomaCTCL cell linesHistone deacetylase inhibitionGeneralized cytotoxic effectExpression of Bcl2Advanced diseaseSuch patientsPeripheral bloodTreatment optionsJAK/STAT pathwayT lymphocytesPreclinical assessmentTherapeutic targetStrong potentiationExtrinsic apoptosis pathwayDeacetylase inhibition
2019
676 Exploring novel therapeutic targets in the treatment of cutaneous T-cell lymphoma
Yumeen S, King A, Kim S, Lewis J, Carlson K, Umlauf S, Surovtseva Y, Foss F, Girardi M. 676 Exploring novel therapeutic targets in the treatment of cutaneous T-cell lymphoma. Journal Of Investigative Dermatology 2019, 139: s116. DOI: 10.1016/j.jid.2019.03.752.Peer-Reviewed Original Research
2014
Stress‐Related Alcohol Consumption in Heavy Drinkers Correlates with Expression of miR‐10a, miR‐21, and Components of the TAR‐RNA‐Binding Protein‐Associated Complex
Beech RD, Leffert JJ, Lin A, Hong KA, Hansen J, Umlauf S, Mane S, Zhao H, Sinha R. Stress‐Related Alcohol Consumption in Heavy Drinkers Correlates with Expression of miR‐10a, miR‐21, and Components of the TAR‐RNA‐Binding Protein‐Associated Complex. Alcohol Clinical And Experimental Research 2014, 38: 2743-2753. PMID: 25421511, PMCID: PMC4244644, DOI: 10.1111/acer.12549.Peer-Reviewed Original ResearchConceptsMiR-21Psychological stressMD subjectsAcute psychological stressReal-time polymerase chain reactionQuantitative real-time polymerase chain reactionGene expressionAlcohol intakeHD groupPeripheral bloodStress-related drinkingPolymerase chain reactionStimulus presentationModerate drinkersMD groupAlcohol-related cuesDrinking subjectsStress-induced drinkingAlcohol consumptionHeavy drinkersAlcohol dependenceAmount of beerMicroRNA-10aChain reactionMicroRNA-21
2013
Gene-expression differences in peripheral blood between lithium responders and non-responders in the Lithium Treatment-Moderate dose Use Study (LiTMUS)
Beech RD, Leffert JJ, Lin A, Sylvia LG, Umlauf S, Mane S, Zhao H, Bowden C, Calabrese JR, Friedman ES, Ketter TA, Iosifescu DV, Reilly-Harrington NA, Ostacher M, Thase ME, Nierenberg A. Gene-expression differences in peripheral blood between lithium responders and non-responders in the Lithium Treatment-Moderate dose Use Study (LiTMUS). The Pharmacogenomics Journal 2013, 14: 182-191. PMID: 23670706, DOI: 10.1038/tpj.2013.16.Peer-Reviewed Original ResearchConceptsPeripheral bloodTreatment responseLithium Treatment Moderate-Dose Use StudyLi respondersClinical responseTreatment initiationTreatment respondersMood symptomsLithium respondersEarly markerBipolar disorderRespondersBloodPatientsGene expression differencesSpecific roleSubjectsResponseBiochemical levelSymptomsDifferencesMonths